Assessment of primary care practitioners' attitudes and interest in pharmacogenomic testing.

Aims: Identify the attitudes and interests of primary care providers (PCPs) in applying clinical pharmacogenomics (PGx) test results. Materials & methods: A questionnaire was designed and then disseminated to PCPs across the MedStar Health System. Results: Ninety of 312 (29%) PCPs responded and were included in analyses. Seventy-six (84%) had heard of PGx and 12 (13%) previously ordered PGx testing. Most, 68 (76%), believed PGx can improve care; however, a minority, 23 (26%), reported confidence in using PGx in prescribing decisions. Sixty-four (70%) wanted a pharmacist consultation. PCPs desired PGx for antidepressants (75%), proton pump inhibitors (72%) and other medications. Conclusion: Most PCPs felt unprepared to interpret PGx results and desired pharmacist consultations. These data can inform future PGx implementations with PCPs.

[1]  L. Gong,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti‐Inflammatory Drugs , 2020, Clinical pharmacology and therapeutics.

[2]  Laura J. Damschroder,et al.  Clarity out of chaos: Use of theory in implementation research , 2020, Psychiatry Research.

[3]  E. Haut,et al.  Practical Guide to Implementation Science. , 2020, JAMA surgery.

[4]  B. Peshkin,et al.  Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings , 2020, Clinical and translational science.

[5]  Yanting Wang,et al.  Opportunities for pharmacists to integrate pharmacogenomics into clinical practice , 2019, The Pharmacogenomics Journal.

[6]  D. Cook,et al.  Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre‐emptive pharmacogenomic testing , 2019, British journal of clinical pharmacology.

[7]  L. Cavallari,et al.  ASHP Statement on the Pharmacist's Role in Clinical Pharmacogenomics. , 2019, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[8]  C. Aquilante,et al.  Precision pharmacotherapy: Integrating pharmacogenomics into clinical pharmacy practice , 2019, Journal of the American College of Clinical Pharmacy : JACCP.

[9]  Michael A. Smith,et al.  PRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas , 2019, Journal of the American College of Clinical Pharmacy.

[10]  R. Shelton,et al.  Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. , 2019, Journal of psychiatric research.

[11]  R. Shelton,et al.  Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing , 2019, Genetics in Medicine.

[12]  R. Fillingim,et al.  CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial , 2019, Genetics in Medicine.

[13]  D. Oslin,et al.  VA Primary Care and Mental Health Providers’ Comfort with Genetic Testing: Survey Results from the PRIME Care Study , 2019, Journal of General Internal Medicine.

[14]  Kristin A. Maloney,et al.  Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype‐Guided Antiplatelet Therapy , 2018, Clinical pharmacology and therapeutics.

[15]  J. Kennedy,et al.  Combinatorial pharmacogenomics and improved patient outcomes in depression: Treatment by primary care physicians or psychiatrists. , 2018, Journal of psychiatric research.

[16]  A. Ramirez,et al.  Physician-Reported Benefits and Barriers to Clinical Implementation of Genomic Medicine: A Multi-Site IGNITE-Network Survey , 2018, Journal of personalized medicine.

[17]  Marylyn D. Ritchie,et al.  Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects , 2018, Clinical pharmacology and therapeutics.

[18]  Matthew Hiller,et al.  A model for rigorously applying the Exploration, Preparation, Implementation, Sustainment (EPIS) framework in the design and measurement of a large scale collaborative multi-site study , 2018, Health & justice.

[19]  P. Hulick,et al.  Patient perspectives following pharmacogenomics results disclosure in an integrated health system. , 2018, Pharmacogenomics.

[20]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update , 2017, Clinical pharmacology and therapeutics.

[21]  K. Sangkuhl,et al.  Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update , 2017, Clinical pharmacology and therapeutics.

[22]  K. Sangkuhl,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors , 2015, Clinical pharmacology and therapeutics.

[23]  R. Nahin.  Estimates of pain prevalence and severity in adults: United States, 2012. , 2015, The journal of pain : official journal of the American Pain Society.

[24]  B. Hemmelgarn,et al.  Exploring physician specialist response rates to web-based surveys , 2015, BMC Medical Research Methodology.

[25]  C. Formea,et al.  Clinical perspective on the Clinical Pharmacogenetics Implementation Consortium Updated 2014 guidelines for CYP2D6 and codeine. , 2015, Clinical chemistry.

[26]  Teri E Klein,et al.  Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. , 2015, Annual review of pharmacology and toxicology.

[27]  Julie A. Johnson,et al.  Emerging Roles for Pharmacists in Clinical Implementation of Pharmacogenomics , 2014, Pharmacotherapy.

[28]  L Gong,et al.  The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update , 2014, Clinical pharmacology and therapeutics.

[29]  T. Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update , 2014, Clinical pharmacology and therapy.

[30]  Teri E. Klein,et al.  Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process , 2014, Current drug metabolism.

[31]  Peggy Brickman,et al.  Best Practices for Measuring Students’ Attitudes toward Learning Science , 2013, CBE life sciences education.

[32]  Cara B. Litvin,et al.  The Prevalence of Chronic Diseases and Multimorbidity in Primary Care Practice: A PPRNet Report , 2013, The Journal of the American Board of Family Medicine.

[33]  J. Mega,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update , 2013, Clinical pharmacology and therapeutics.

[34]  W Burke,et al.  Primary care physicians' knowledge of and experience with pharmacogenetic testing , 2012, Clinical genetics.

[35]  Melissa A. Basford,et al.  Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping , 2012, Clinical pharmacology and therapeutics.

[36]  G. Aarons,et al.  Advancing a Conceptual Model of Evidence-Based Practice Implementation in Public Service Sectors , 2010, Administration and Policy in Mental Health and Mental Health Services Research.

[37]  G. Norman.  Likert scales, levels of measurement and the “laws” of statistics , 2010, Advances in health sciences education : theory and practice.